--- title: "Puma Biotechnology Raises Outlook Despite Q1 Reset" type: "News" locale: "en" url: "https://longbridge.com/en/news/285785744.md" description: "Puma Biotechnology (PBYI) reported a Q1 revenue of $44.8 million, down from the previous quarter, but raised its full-year guidance for NERLYNX revenue to $202-$206 million. The company emphasized a debt-free balance sheet and improving commercial execution, with a 25% increase in new prescriptions. Interim data from alisertib trials showed promising results in lung and breast cancer. Despite a revenue drop due to royalty and inventory issues, Puma's cash position improved to $101.5 million, and R&D spending is expected to rise significantly in 2026." datetime: "2026-05-09T00:20:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285785744.md) - [en](https://longbridge.com/en/news/285785744.md) - [zh-HK](https://longbridge.com/zh-HK/news/285785744.md) --- # Puma Biotechnology Raises Outlook Despite Q1 Reset Puma Biotechnology ((PBYI)) has held its Q1 earnings call. Read on for the main highlights of the call. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Puma Biotechnology’s latest earnings call struck a cautiously optimistic tone despite a sharp sequential drop in first‑quarter revenue and royalties. Management emphasized stronger full‑year guidance, a debt‑free balance sheet and improving commercial execution, while highlighting encouraging early data from its alisertib oncology program, suggesting that near‑term headwinds may be outweighed by longer‑term growth drivers. ## Q1 Revenue Reset but Full‑Year Outlook Raised Puma reported Q1 2026 total revenue of $44.8 million, with NERLYNX net product sales of $42.0 million, down sharply from the prior quarter. Even so, the company lifted its full‑year 2026 NERLYNX revenue guidance to $202 million–$206 million and now expects net income of $16 million–$19 million, with Q2 product revenue targeted at $50 million–$52 million and net income of $2 million–$4 million. ## Commercial Demand and Field Activity Trending Higher Underlying demand showed improvement despite quarterly volatility, with new prescriptions rising about 25% sequentially and 11% year over year and enrollments up roughly 10% quarter over quarter. Commercial call activity climbed 44% versus a year ago and 14% versus Q4, supporting an approximately 7% year‑over‑year increase in overall demand for NERLYNX. ## International Expansion and Specialty Channels Support Growth Puma continued to broaden NERLYNX’s global reach, including a recent launch in Thailand in the extended adjuvant setting. The specialty distributor channel delivered about 28% year‑over‑year growth, helping to underpin wider adoption and diversify the company’s revenue base beyond its core U.S. market. ## Debt‑Free Balance Sheet and Modest Cash Burn The company exited Q1 debt‑free after making its final loan payment, ending March with approximately $101.5 million in cash, cash equivalents and marketable securities, up from $97.5 million at year‑end. Cash burn was about $4 million in the quarter, while accounts receivable stood at $26.3 million and distribution inventory remained around three weeks, giving Puma room to fund its clinical and commercial plans. ## Alisertib Shows Biomarker‑Linked Signal in Lung Cancer Interim data from the ALISCA‑Lung1 trial showed dose‑dependent activity for alisertib with emerging biomarker guidance, including a 11.5% partial response rate and 1.7‑month median progression‑free survival at 50 mg. Patients with higher c‑Myc H‑scores saw median progression‑free survival of 4.17 months versus 1.68 months for lower scores, suggesting enhanced benefit in c‑Myc‑driven tumors. ## Breast Cancer Data Highlight Targeted Subgroups In the ALISCA‑Breast1 study, interim combination data across 164 patients indicated stronger outcomes at higher doses and in biomarker‑defined subgroups, with median progression‑free survival of 5.45 months at 40 mg and 5.59 months at 50 mg. Patients with c‑Myc copy number above two achieved median progression‑free survival of 7.29 months, and ESR1‑mutant, PIK3CA wild‑type cohorts showed encouraging durability, prompting plans to expand those groups in the second half of 2026. ## Safety Enhancements and Next‑Step Trial Designs ALISCA‑Lung1 incorporated mandatory prophylactic G‑CSF and showed reduced rates of Grade 3 or higher neutropenia at both 50 mg and 60 mg compared with historical experience, enabling exploration of a 70 mg dose. Puma is preparing ALISCA‑Lung2, a combination of alisertib with paclitaxel using the same G‑CSF prophylaxis, with initiation targeted for the second half of 2026 to further refine dose and regimen. ## Revenue Drop Driven by Royalty and Inventory Swings Q1 net product revenue fell from $59.9 million in Q4 2025 to $42.0 million, including U.S. sales of $41.8 million versus $55.2 million previously. Royalty revenue plunged to $2.8 million from $15.6 million due to a large one‑time shipment to the China partner in Q4, while an inventory drawdown of about 439 bottles reduced reported product revenue by approximately $7.9 million. ## Ex‑Factory Sales, Gross‑to‑Net and Demand Headwinds Ex‑factory bottle sales were 2,328 in Q1, down roughly 29% from Q4 but essentially flat year over year, reflecting channel dynamics rather than underlying erosion. Total prescriptions slipped about 4% sequentially and overall commercial demand declined around 6% quarter over quarter, as specialty distributor buying patterns and elevated gross‑to‑net rates near 27% weighed on reported results. ## Higher Gross‑to‑Net and Rising R&D Investment Puma’s gross‑to‑net adjustment remained elevated at roughly 27% in Q1, driven by government chargebacks and a heavier Medicare and Medicaid mix, with management expecting 26.5%–27.5% for the year and 27%–28% in Q2. Research and development spending rose to $19.8 million, and the company projects R&D to increase 34%–37% year over year in 2026, with SG&A up 1%–2%, implying a higher operating cost base and modestly greater cash usage. ## Managing Safety Risks at Higher Breast Doses In ALISCA‑Breast1, Grade 3 or higher neutropenia reached 26.9% in the 50 mg arm, where prophylactic G‑CSF was not mandated, raising tolerability concerns at the upper dose. These safety findings may necessitate additional supportive care or adjustments to dosing strategy as Puma seeks to balance efficacy advantages in biomarker‑selected patients with an acceptable safety profile. ## Guidance Underlines Confidence Despite Volatility Management’s guidance calls for 2026 NERLYNX net product revenue of $202 million–$206 million and royalties of $20 million–$23 million, with no planned license revenue and full‑year net income of $16 million–$19 million. For Q2, Puma anticipates $50 million–$52 million in product revenue, $2 million–$3 million in royalties and net income of $2 million–$4 million, while remaining debt‑free and continuing to invest heavily in R&D and its alisertib development program. Puma Biotechnology’s call painted a picture of a company absorbing short‑term revenue noise while leaning into a stronger 2026 outlook and a more robust pipeline story. Investors will be watching whether improved field metrics and international expansion translate into steadier top‑line growth and whether alisertib’s biomarker‑driven strategy can evolve into a meaningful new revenue stream over the next few years. ### Related Stocks - [PBYI.US](https://longbridge.com/en/quote/PBYI.US.md) ## Related News & Research - [Puma Biotech CFO Maximo F. Nougues disposes of 9,386 shares for $77,560.24](https://longbridge.com/en/news/292125961.md) - [Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday](https://longbridge.com/en/news/284763454.md) - [REG - Intnl. Biotechnology - Holding(s) in Company](https://longbridge.com/en/news/293638702.md) - [Bollard Group LLC Reduces Position in Aclaris Therapeutics, Inc. $ACRS](https://longbridge.com/en/news/293815783.md) - [Bank of New York Mellon Corp Reduces Stock Position in Ascendis Pharma A/S $ASND](https://longbridge.com/en/news/293716720.md)